Published 09/25/2024 7:53:08 p.m.

FDA Expands Approval of Osimertinib in Lung Cancer

Summary by MedPage Today

The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, the

0 Articles

All

Left

Center

Right

MedPage Today

FDA Expands Approval of Osimertinib in Lung Cancer

The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, the

09/25/2024 9:40:25 p.m.·New York, United States

Read Full Article

pipelinereview

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer - Pipelinereview

Based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival by more than three years LONDON, UK I September 26, 2024 I AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or seq…

09/26/2024 6:54:10 a.m.

Read Full Article

onclive.com

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.

09/25/2024 7:36:45 p.m.

Read Full Article

Pharmacy Times

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

The decision is based on positive results from the phase 3 LAURA trial.

09/26/2024 12:52:59 p.m.

Read Full Article

targetedonc.com

FDA Approves Osimertinib in Stage III EGFR-Mutated NSCLC

Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that did not progress during or following platinum-based chemoradiation.

09/25/2024 8:13:00 p.m.

Read Full Article

cancernetwork.com

FDA Approves Osimertinib in Advanced EGFR+ NSCLC

Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.

09/25/2024 7:53:08 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated09/26/2024 1:23:27 p.m.Bias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

FDA Expands Approval of Osimertinib in Lung Cancer

0 Articles

0 Articles

FDA Expands Approval of Osimertinib in Lung Cancer

FDA Expands Approval of Osimertinib in Lung Cancer

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer - Pipelinereview

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer - Pipelinereview

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

FDA Approves Osimertinib in Stage III EGFR-Mutated NSCLC

FDA Approves Osimertinib in Stage III EGFR-Mutated NSCLC

FDA Approves Osimertinib in Advanced EGFR+ NSCLC

FDA Approves Osimertinib in Advanced EGFR+ NSCLC

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics